Trial of Controversial Alzheimer’s Drug Halted After Disappointing Results

Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate Alzheimer’s disease.

By Teddy Rosenbluth | NYTimes | NYT > Business | Disclosure